Regenerative Therapy

Tumor Immunology and Immunotherapy
Nature Reviews Issue dedicated entierly to the subject.
http://www.nature.com/reviews/focus/tumourimmunology/index.html

Report on intermediate results of clinical study:
The publication showed that a single non-surgical injection of Mesoblast’s allogeneic mesenchymal progenitor cells (MPCs) into damaged intervertebral discs resulted in significant regeneration of disc anatomy, increase in proteoglycan content, and increase in disc height, for at least six months.
Published in:
Journal of Neurosurgery, Posted online on March 9, 2012
Entitled “Immunoselected STRO-3+mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs”, can be viewed at:
http://thejns.org/doi/full/10.3171/2012.1.SPINE11852
Mesoblast, Australia

 Paper title:
“Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial”
Richard J Powell et al. Molecular Therapy ( April 2012)
From the abstract:
“Ixmyelocel-T is a patient-specific, expanded, multicellular therapy evaluated in patients with lower extremity critical limb ischemia (CLI) with no options for revascularization. This randomized, double-blind, placebo-controlled, phase 2 trial (RESTORE-CLI) compared the efficacy and safety of intramuscular injections of ixmyelocel-T with placebo. 
“ Ixmyelocel-T treatment was well tolerated and may offer …

A new review article on adoptive immunotherapy by Steve Rosenberg:
Sci Transl Med. 2012 Mar 28;4(127):
“Raising the bar: the curative potential of human cancer immunotherapy”.
PubMed:  http://www.ncbi.nlm.nih.gov/pubmed/22461638

Abstract
“Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides …

Title:
Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients.
Glass JD, et al Stem Cells. 2012 Mar 13. [Epub ahead of print]
Abstract:
http://www.ncbi.nlm.nih.gov/pubmed/22415942.1
Phase I safety trial of intraspinal injections of fetal-derived neural stems cells in patients with Amyotrophic Lateral Sclerosis (ALS).
Emory University School of Medicine, Atlanta, GA USA

CYTORI BREAST RECONSTRUCTION CELL THERAPY TRIAL RESULTS PUBLISHED
http://ir.cytori.com/InvestorRelations/releasedetail.cfm?ReleaseID=657974
Published in:
“Prospective trial of Adipose-Derived Regenerative Cell (ADRC)-enriched fat grafting for partial mastectomy defects: The RESTORE-2 trial”
R. Pérez-Canoa, J.J. Vranckxb, J.M. Lassoa, C. Calabresec, B. Merckd, A.M. Milsteine, E. Sassoonf, E. Delayg, E.M. Weiler-Mithoffh,
European Journal of Surgical Oncology – March 2012

Abstract:
Title: “Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation.”
Induction of immune tolerence by organ donor hematopoietic stem cells enables kidney transplant following immune suppression.
“These results suggest that manipulation of a mobilized stem cell graft and nonmyeloablative conditioning represents a safe, practical, and reproducible means of inducing durable chimerism and donor-specific tolerance in solid organ transplant recipients.”
Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud …

“Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa.”
“Healthy donor cells from the hematopoietic graft migrate to the injured skin; simultaneously, there is an increase in the production of collagen type VII, increased skin integrity, and reduced tendency to blister formation.”
Tolar J, Blazar BR, Wagner JE. 
Published in:
Stem Cells. 2011 Jun;29(6):900
http://www.ncbi.nlm.nih.gov/pubmed/21557391

“Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells.”
Zhao y. et al 2012 BMC Med. 10;10(1):3
“Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment …

Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon
BMC Medicine 2012, 10:3  http://www.biomedcentral.com/1741-7015/10/3/abstract
“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them …